Healthy Skepticism Library item: 1147
Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.
Publication type: Journal Article
Woloshin S, Schwartz LM, Welch HG.
The value of benefit data in direct-to-consumer drug ads.
Health Aff (Millwood) 2004 Jan-Jun; Suppl Web Exclusives:W4-234-45
http://content.healthaffairs.org/cgi/reprint/hlthaff.w4.234v1
Abstract:
Direct-to-consumer (DTC) pharmaceutical ads typically describe drug benefits in qualitative terms; they rarely provide data on how well the drug works. We describe an evaluation of a “prescription drug benefit box”-data from the main randomized trials on the chances of various outcomes with and without the drug. Most participants rated the information as “very important” or “important”; almost all found the data easy to understand. Perceptions of drug effectiveness were much lower for ads that incorporated the benefit box than for ads that did not. Most people we interviewed want benefit data in drug ads, can understand these data, and are influenced by them.
Keywords:
Adult
Advertising/methods*
Aged
Consumer Participation*
Drug Industry/organization & administration*
Female
Humans
Male
Middle Aged
Pharmaceutical Preparations*
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.
United States
